ABVC BioPharma Inc. (ABVC)

Overview

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company based in Fremont, California. It focuses on developing drugs and medical devices aimed at fulfilling unmet medical needs within the United States healthcare market. The company is dedicated to advancing a wide range of therapies across various stages of clinical trials, targeting diseases with high unmet medical needs including cancer, major depressive disorders, adult attention deficit hyperactivity disorder, myelodysplastic syndromes, and more. Operating as a subsidiary of YuanGene Corporation, ABVC BioPharma, Inc. has established co-development and collaboration agreements with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation to bolster its research and development efforts.

Products and Services

• ABV-1501

  Currently in Phase II clinical trials, ABV-1501 is a combination therapy aimed at treating triple negative breast cancer, a specific cancer subtype known for its lack of three common receptors found in other breast cancers.

• ABV-1504

  ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. This development represents ABVC BioPharma’s efforts in addressing mental health conditions with effective treatment options.

• ABV-1505

  In Phase II clinical trials, ABV-1505 is being studied for its potential to treat adult attention deficit hyperactivity disorder (ADHD), targeting adults who continue to suffer from or are diagnosed with ADHD later in life.

• ABV-1703

  ABV-1703 is under Phase II clinical trials for treating metastatic pancreatic cancer, focusing on one of the most aggressive and deadly forms of cancer by seeking to improve outcomes and survival rates for patients.

• ABV-1702

  Currently in Phase II clinical trials, ABV-1702 aims to treat myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow do not mature into healthy blood cells.

• ABV-1601

  ABV-1601 is being tested in Phase I/II clinical trials for its potential to treat depression in cancer patients, targeting the emotional and psychological challenges faced by individuals battling cancer.

• ABV-1701 Vitargus

  In Phase II clinical trials, ABV-1701 Vitargus is being developed for the treatment of retinal detachment or vitreous hemorrhage, aiming to improve treatment options for these serious eye conditions.

• ABV-1519

  Currently in Phase I/II clinical trials, ABV-1519 is being developed to treat non-small cell lung cancer, one of the most common types of lung cancer, signaling ABVC BioPharma’s commitment to combatting this deadly disease.